

Orange Biomed to Unveil Portable Glycated Hemoglobin Meter at CES 2025

Reporter Oh In-gyu | Approved 2025.01.01 02:22

[Medical Newspaper/Daily Newspaper=Reporter In-gyu Oh] Orange Biomed (CEO Woong-hyun Koh, Yeseul Park) announced that it will be participating in Eureka Park at CES 2025, held in Las Vegas, Nevada, USA from January 7 to 10, and will be introducing the portable glycated hemoglobin measuring device, 'OBM rapid A1c'.



'OBM rapid A1c' is the world's first device to use microfluidic technology to measure glycated hemoglobin, and is an innovative solution that allows anyone to easily measure glycated hemoglobin with just one drop of blood.

Unlike blood sugar, glycated hemoglobin (HbA1c) is stable and reliable regardless of the time of day, and is used as an important indicator to evaluate the blood sugar control status of diabetic patients.

Glycated hemoglobin increases blood viscosity, damages blood vessels and surrounding tissues, and causes various diabetic complications.

CEO Park Ye-seul said, "It is meaningful to introduce a medical device that allows easy and accurate glycated hemoglobin testing, which is essential for diabetes management, at CES 2025, the world's largest consumer electronics show hosted by the Consumer Technology Association (CTA) in the United States."

He emphasized, “Many people have difficulty managing diabetes complications due to poor accessibility to hospitals, and we want to increase medical equity by making cutting-edge medical technology accessible to patients at home, the closest place to them.”



Reporter Oh In-gyu 529@bosa.co.kr

Copyright © Medical Newspaper. Unauthorized reproduction and redistribution prohibited.